-
Keryx Biopharmaceuticals Surges 20% Following Positive Kidney Disease Drug Data
Tuesday, March 29, 2016 - 8:54am | 241Read More...Shares of Keryx Biopharmaceuticals (NASDAQ: KERX), a biopharmaceutical company that focuses on the treatment of renal diseases, gained more than 20 percent early Tuesday morning. Keryx Biopharmaceuticals announced positive top-line results from its pivotal Phase 3 study of ferric citrate for the...
-
Illumina and Other Bargain Biotech Stocks Worth a Look Now
Wednesday, May 1, 2013 - 12:57pm | 916Read More...The research team at PropThink, which focuses on emerging growth companies in the health care sector, recently offered a list of bargain biotech stocks worth a look. The stocks that made the list include Endo Health Solutions (NASDAQ: ENDP), Illumina (NASDAQ: ILMN) and Keryx Biopharmaceuticals (...
-
UPDATE: Oppenheimer Raises PT on KERYX Biopharmaceuticals to $8
Tuesday, June 7, 2011 - 7:20am | 121Read More...Oppenheimer is out with its report today on KERYX Biopharmaceuticals (NASDAQ: KERX), raising its PT from $7 to $8. In a note to clients, Oppenheimer writes, "We recently revisited our assumption behind perifosine's commercial projections, including the intellectual property associated with the...
-
Oppenheimer Raises PT On KERX To $8
Tuesday, June 7, 2011 - 6:12am | 26Read More...Oppenheimer has raised the price target on KERYX Biopharmaceuticals (NASDAQ: KERX) from $7 to $8 and maintains its Outperform rating.
